Meg Moloney is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on corporate and securities work for both public and private companies across all stages of growth. Meg's broad capital markets experience includes representing issuers and investment banks in connection with initial public, follow-on, secondary equity, and tender offerings. She also counsels publicly traded companies on general corporate matters, SEC compliance, disclosure matters, exchange listing standards, and complex securities law issues.
Prior to joining the firm, Meg practiced law at Fenwick & West LLP in New York.
Meg Moloney is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on corporate and securities work for both public and private companies across all stages of growth. Meg's broad capital markets experience includes representing issuers and investment banks in connection with initial public, follow-on, secondary equity, and tender offerings. She also counsels publicly traded companies on general corporate matters, SEC compliance, disclosure matters, exchange listing standards, and complex securities law issues.
Prior to joining the firm, Meg practiced law at Fenwick & West LLP in New York.
- J.D., University of Fordham Law School
- B.A., Fordham College
- State Bar of New York
- J.D., University of Fordham Law School
- B.A., Fordham College
- State Bar of New York
Select Matters
- Represented Figma, Inc. in its initial public offering*
- Represented CoreWeave, Inc. in its initial public offering*
- Represented BioAge Labs, Inc. in its initial public offering*
- Represented the underwriters in the initial public offering of MNTN, Inc.*
- Represented Day One Biopharmaceuticals, Inc. in its acquisition of Mersana Therapeutics, Inc.*
- Represented Alpine Immune Sciences, Inc. in its acquisition by Vertex Pharmaceuticals Incorporated*
- Represented Pardes Biosciences in its acquisition by MediPacific, Inc.*
*Denotes matters handled at another firm prior to joining Wilson Sonsini in 2026
Select Matters
- Represented Figma, Inc. in its initial public offering*
- Represented CoreWeave, Inc. in its initial public offering*
- Represented BioAge Labs, Inc. in its initial public offering*
- Represented the underwriters in the initial public offering of MNTN, Inc.*
- Represented Day One Biopharmaceuticals, Inc. in its acquisition of Mersana Therapeutics, Inc.*
- Represented Alpine Immune Sciences, Inc. in its acquisition by Vertex Pharmaceuticals Incorporated*
- Represented Pardes Biosciences in its acquisition by MediPacific, Inc.*
*Denotes matters handled at another firm prior to joining Wilson Sonsini in 2026
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
- Privacy Policy
- Terms of Use
- Accessibility